ClinicalTrials.gg
CompletedNCT03392779Updated Aug 13, 2019

Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics

A Phase 1 interventional study of ZSP1601 25 mg and Placebo 25mg in Nonalcoholic Steatohepatitis (NASH), sponsored by Guangdong Zhongsheng Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-13.

Sponsored by Guangdong Zhongsheng Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 54 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Enrollment
52nd of 89
94 · median 112
Started
2018
with 7 others
Phase 1
18 of 142
4 open now
Registered
27th of 142
by date

Among the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 52nd largest by enrollment of the 89 interventional ones that give a count, is one of 8 that started in 2018, is one of 18 in phase 1, and was the 27th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 142 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of ZSP1601 on fasted condition, and characterize PK of ZSP1601 on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence manner. The study will be conducted in 3 parts (Ascending single dose, multiple dose and food effect). Participants will receive either ZSP1601 or placebo .

Read the detailed description

The study is a randomized, double-blind phase 1 trial including 3 parts: single ascending dose(SAD) part,multiple ascending dose(MAD) part and postprandial pharmacokinetics part.The primary aims of the study as below:

Evaluating the safety and tolerance of single and multiple dose of ZSP1601 in healthy volunteers.

Evaluating the fasting and postprandial pharmacokinetic parameters of ZSP1601 in healthy volunteers.

Eligible participants will be admitted to the trial center on Day -1. Subjects will be randomly assigned to either experimental groups or placebo groups, according to a randomisation schedule in a (4:1) ratio (8 in per experimental group). Subjects in SAD will receive 25、50、100、175、275、350 mg once daily respectively.Each dose will be administrated after assurance of safety for the former dose. Subjects in MAD will receive 50 or 100 mg once daily for 14days respectively.The treatment in food effect consists of 2 periods,and subjects will receive 100mg on fasting and postprandial states respectively. There will be a 7-day wash out period between treatment periods.To monitor AEs,record abnormalities (12-lead ECG,Vital signs,Physical examination,Clinical Laboratory),and detect the pharmacokinetics of ZSP1601.

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects are required to meet the following criteria in order to be included in the trial:

    1. Signature of a dated Form (ICF) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.
    2. Subjects must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.
    3. Subjects(including partners)have no gestation plans and must use reliable methods of during the study and until 6 months following the last dose of product.
    4. Males and female subjects between 18-50 years (Both inclusive).
    5. Body weight is no less than 50kg in males and no less than 45kg in females. (BMI) 18≤BMI≤28 kg/m2; BMI is determined by the following equation: BMI = weight/height2 (kg/m2).
    6. Physical condition:No significant abnormalities in medical history, including cardiovascular system, liver, kidneys, gastrointestinal system, neural system, respiratory system (eg.asthma,asthma induced by exercise,), mental, metabolism, etc.
    7. Subjects in general good health or No significant abnormalities in the opinion of the investigator as determined by vital signs and a physical examination.

Exclusion criteria

Exclusion Criteria:

  • Eligible subjects must not meet any of the following exclusion criteria:

    1. The average daily smoking are more than 5 cigarettes within 3 months prior to screening.
    2. Known and/or allergy to some drugs and food.
    3. Known history of drug or alcohol abuse.(defined as consumption of 14 units of alcohol per week:1 unit=285ml of beer; or the equivalent of 25ml of spirit, or 100ml of wine )
    4. Subjects who donated blood or bleeding profusely(> 400 mL)in the 3 months preceding study screening.
    5. Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs.
    6. History or presence of any disease or condition known to increase the risk of bleeding, eg.acute gastritis, duodenal ulcer, etc.
    7. Frequently suffers from postural hypotension.
    8. History of frequent nausea or vomit causes by any etiology.
    9. Concomitant therapy with any drugs with known hepatic enzyme-inducing or inhibiting agents that may change the activity of prior to screening or during the study.
    10. Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal or dietary supplements within 14 days prior to screening.
    11. History of having any special food(including dragon fruit,mango,grapefruit,etc.),strenuous exercises,or other factors may interfere with the absorption, distribution, metabolism, or excretion of drug within 14 days prior to screening.
    12. Subjects with recent significant change in diet or exercise .
    13. Participated in another clinical research study and received any products within 3 months prior to dosing.
    14. Inability to consume the food provided in the study ( a high fat, high calorie meal includes two eggs for 100g, bacon 20g, a butter toast for 50g, french fries for 115g, whole milk for 240ml).This requirement only applies to subjects under fed condition.
    15. Presence of abnormalities in or >470ms in males,or QTc>480ms in females.
    16. Pregnancy or breastfeeding at screening and during the study.All female subjects of must have a negative urine pregnancy test at screening and during the trial.
    17. Any clinically significant abnormality upon physical examination or in the clinical laboratory tests. History or presence of a clinically significant gastrointestinal, renal, hepatic, neurologic, hematic, endocrine, neoplastic, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular disorder(s) (but not limited to above disorders).
    18. Presence of (HIV), viral hepatitis(including virus (HCV) or virus (HBV) ),treponema pallidum antibodies at screening.
    19. Any acute illness or concomitant medication from screening to first dosing.
    20. Have chocolate, any food or beverage that contains caffeine or xanthine within 24 hours prior to dosing.
    21. Take any product contains alcohol within 24 hours prior to dosing.
    22. Positive for urine drug screening or history of substance abuse for a period of 5 consecutive years before screening.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    ZSP1601(single dose)-25 mg while fasted(Cohort 1)

    ZSP1601 25 mg /Placebo

    Drug: ZSP1601 25 mg · Drug: Placebo 25mg

  • Experimental
    ZSP1601(single dose)-50 mg while fasted(Cohort 2)

    ZSP1601 50 mg/Placebo Enrollment into Cohort 2 will begin upon assurance of safety for Cohort 1.

    Drug: ZSP1601 50 mg · Drug: Placebo 50 mg

  • Experimental
    ZSP1601(single dose)-100 mg while fasted(Cohort 3)

    ZSP1601 100 mg/Placebo Enrollment into Cohort 3 will begin upon assurance of safety for Cohort 2.

    Drug: ZSP1601 100 mg · Drug: Placebo 100 mg

  • Experimental
    ZSP1601(single dose)-175 mg while fasted(Cohort 4)

    ZSP1601 175 mg/Placebo Enrollment into Cohort 4 will begin upon assurance of safety for Cohort 3.

    Drug: ZSP1601 175 mg · Drug: Placebo 175 mg

  • Experimental
    ZSP1601(single dose)-275 mg while fasted(Cohort 5,i.e.Group A)

    ZSP1601 275 mg/Placebo Enrollment into Cohort 5 will begin upon assurance of safety for Cohort 4.

    Drug: ZSP1601 275 mg · Drug: Placebo 275 mg

  • Experimental
    ZSP1601(single dose)-350 mg while fasted(Cohort 6)

    ZSP1601 350 mg/Placebo Enrollment into Cohort 6 will begin upon assurance of safety for Cohort 5.

    Drug: ZSP1601 350 mg · Drug: Placebo 350mg

  • Experimental
    ZSP1601(food effect)-100 mg (Cohort FE)

    Period 1 (Day1 to Day4): Group A and Group B receive ZSP1601 100 mg/Placebo under the fasting or fed condition ,respectively on Day1. Period 2 (Day 8 to Day11): Group A and Group B receive ZSP1601 100 mg/Placebo under the fed or fasting condition ,respectively on Day8.

    Drug: ZSP1601 100 mg · Drug: Placebo 100mg

  • Experimental
    ZSP1601(multiple doses)-50 mg (Cohort 7)

    50 mg ZSP1601 will be administrated while fasted or fed according to the results of Cohort FE ZSP1601 50 mg/Placebo for 14 Days.

    Drug: ZSP1601 50 mg · Drug: Placebo 50 mg

  • Experimental
    ZSP1601(multiple doses)-100 mg (Cohort 8)

    Enrollment into Cohort 8 will begin upon assurance of safety for Cohort 7. ZSP1601 100 mg/Placebo for 14 Days.

    Drug: ZSP1601 100 mg · Drug: Placebo 100 mg

Interventions

  • ZSP1601 tablet administered orally once daily under fasted condition

  • DrugPlacebo 25mg

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

  • ZSP1601 tablet administered orally once daily under fasted condition

  • DrugPlacebo 50 mg

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

  • ZSP1601 tablets administered orally once daily in the fasting state

  • DrugPlacebo 100 mg

    Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state

  • ZSP1601 tablets administerekd orally once daily under fasted condition

  • DrugPlacebo 175 mg

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

  • ZSP1601 tablets administered orally once daily in the fasting state

  • DrugPlacebo 275 mg

    Participants will receive placebo matching to ZSP1601 orally once daily in the fasting state

  • ZSP1601 tablets administered orally once daily under fasted condition

  • DrugPlacebo 350mg

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted condition

  • ZSP1601 tablets administered orally once daily under fasted or fed condition

  • DrugPlacebo 100mg

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition

  • ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

  • DrugPlacebo 50 mg

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

  • ZSP1601 tablets administered orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

  • DrugPlacebo 100 mg

    Participants will receive placebo matching to ZSP1601 orally once daily under fasted or fed condition due to the results of Cohort FE for 14 Days(a total of 14 doses).

06

What researchers measure

Primary outcomes

  1. Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE) following oral doses(single,multiple and food effect)of ZSP1601 and placebo.

    Time frame: SAD Group: Up to 4 days, MAD: Up to 17days, FE group: Up to 11 days after first dose

  2. Concomitant Medication

    Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively

  3. Clinical Laboratory Abnormalities(Blood routine test, serum biochemical test, conventional coagulation examinations, urine examination ) post dose of ZSP1601 and placebo.

    Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively

  4. 12-lead ECG Abnormalities following oral dosing of ZSP1601 and placebo.

    Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively

  5. Vital signs Abnormalities following oral dosing of ZSP1601 and placebo.

    Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively

  6. Physical examination Abnormalities following oral dossing of ZSP1601 and placebo.

    Time frame: UP to 4, 17, 11 days for SAD, MAD, FE part respectively

  7. Cardiac color ultrasound(UCG) Abnormalities following multiple oral doses of ZSP1601 and placebo.

    Time frame: Screening, Day17

Secondary outcomes

  1. AUClast(AUC0-t)of ZSP1601

    AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.

    Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively

  2. AUCinf(AUC0-∞)of ZSP1601

    AUCinf is defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).

    Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively

  3. Cmax of ZSP1601

    Cmax is defined as the maximum observed concentration of drug in plasma.

    Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively

  4. Tmax of ZSP1601

    Tmax is defined as the time to maximum concentration.

    Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively

  5. t1/2z of ZSP1601

    t1/2z is defined as the time to decline half of the drug concentration in plasma.

    Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively

  6. Single-dose PK Parameter: Ae of ZSP1601

    Ae is defined as the amount of unchanged drug excreted in urine or faeces after administration.

    Time frame: Up to Day 2 post-dose

  7. Single-dose PK Parameter: Fe0-t of ZSP1601

    Fe0-t is defined as the cumulative excretion rate of the drug in urine and feces.

    Time frame: Up to Day 2 post-dose

  8. CL/F of ZSP1601

    CL/F is defined as the ratio of total clearance(Cl) to bioavailability(F).

    Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively

  9. λz of ZSP1601

    λz is defined as the ratio between the elimination of compound per unit time and the total amount of compound.

    Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively

  10. CLr of ZSP1601

    CLr is defined as how many milliliters of plasma in which some substance can be completely eliminated in the unit time (per minute) of two kidneys

    Time frame: UP to 2, 16, 9 days for SAD, MAD, FE part respectively

  11. Multiple-dose plasma PK parameter: Rac of ZSP1601 at steady state

    Rac (Accumulation Index) is defined as the ratio between AUC0-XX in Day XX and AUC0-XX in Day1

    Time frame: Up to 16days

  12. Multiple-dose plasma PK parameter: DF of ZSP1601 at steady state

    DF is defined as the percentage of fluctuation in steady state is 100 \* (Cmax, ss - Cmin, ss)/Cavg, ss.

    Time frame: Up to 16 days

  13. Multiple-dose plasma PK parameter: Cmin of ZSP1601 at steady state

    Cmin is defined as the minimum observed concentration of drug in plasma at steady state.

    Time frame: Up to 16days

07

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
08

References and documents

Publications

  • Zhu X, Wu M, Wang H, Li H, Lin J, Peng Y, Hu Y, Li C, Ding Y. Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study. Expert Opin Investig Drugs. 2021 May;30(5):579-589. doi: 10.1080/13543784.2021.1900822. Epub 2021 Mar 25. PubMed 33682556 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Dec 2018, 11 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is close to that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2018
First posted
Jan 8, 2018
StartActual
Jan 5, 2018
Primary completionActual
Dec 21, 2018
CompletionActual
Mar 22, 2019
Last update
Aug 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03392779
Responsible party
Sponsor
First posted
Jan 8, 2018
Start date
Jan 5, 2018
Primary completion
Dec 21, 2018
Completion
Mar 22, 2019
Last update
Aug 13, 2019

Study contacts

Yanhua Ding, MD
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZSP1601

Start the discussion